AgomAb Therapeutics (NASDAQ:AGMB) Stock: Insider David Epstein Purchases 10,000 Shares

AgomAb Therapeutics NV (NASDAQ:AGMB) Director David Epstein acquired 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 21st. The stock was acquired at an average price of $8.88 per share, with a total value of $88,800.00. Following the acquisition, the director owned 25,000 shares in the company, valued at $222,000. The trade was a 66.67% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

AgomAb Therapeutics Stock Performance

Shares of NASDAQ AGMB opened at $9.05 on Friday. AgomAb Therapeutics NV has a 52-week low of $7.92 and a 52-week high of $17.82. The firm has a 50 day moving average price of $11.52 and a two-hundred day moving average price of $11.75.

AgomAb Therapeutics (NASDAQ:AGMB) last announced its earnings results on Thursday, August 6th. The company reported ($0.46) EPS for the quarter. On average, equities analysts forecast that AgomAb Therapeutics NV will post -1.77 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on AGMB shares. Cantor Fitzgerald initiated coverage on shares of AgomAb Therapeutics in a research note on Wednesday, August 19th. They issued an “overweight” rating on the stock. B. Riley Financial assumed coverage on shares of AgomAb Therapeutics in a report on Thursday, July 23rd. They issued a “buy” rating and a $34.00 target price on the stock. Johnson Rice reaffirmed a “buy” rating on shares of AgomAb Therapeutics in a research report on Wednesday. Piper Sandler initiated coverage on AgomAb Therapeutics in a report on Tuesday, August 25th. They set an “overweight” rating and a $60.00 price target for the company. Finally, Wall Street Zen lowered AgomAb Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, September 27th. Eight analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $37.50.

Key Headlines Impacting AgomAb Therapeutics

Here are the key news stories impacting AgomAb Therapeutics this week:

• Positive Sentiment: Director David Epstein purchased 10,000 AGMB shares at an average price of $8.88, investing approximately $88,800 and increasing his direct ownership by 66.7% to 25,000 shares. Insider buying can signal management confidence that the stock is undervalued. AgomAb Therapeutics Director Buys 10,000 Shares
• Positive Sentiment: HC Wainwright raised its EPS forecasts for every year from fiscal 2026 through fiscal 2030. The revisions were modest but consistently favorable, with estimated losses narrowing to $1.91 per share in 2026, $2.02 in 2027, $1.75 in 2028, $1.81 in 2029 and $1.79 in 2030. The firm maintained its “Buy” rating.
• Neutral Sentiment: Analyst sentiment remains broadly constructive, with the company described as having a “Moderate Buy” consensus and several firms maintaining Buy or Overweight ratings. However, one research firm recently downgraded the shares to Sell, highlighting disagreement about the company’s outlook.
• Negative Sentiment: AgomAb is still expected to report losses, including a consensus estimate of approximately $1.83 in negative EPS for the current year. As a clinical-stage biotechnology company, its valuation remains dependent on progress in programs such as AGMB-129, while the shares continue to trade below their key moving averages.

AgomAb Therapeutics Company Profile

Agomab Therapeutics N.V. is a clinical-stage biotechnology company focused on developing medicines that promote tissue regeneration and address diseases associated with fibrosis and tissue damage. The company’s research is centered on biological pathways involved in repair, remodeling and the disease microenvironment.

Agomab’s lead program is AGMB-129, an orally administered, gut-restricted small-molecule inhibitor of transforming growth factor beta receptor 1, also known as ALK5. The program is being developed for intestinal fibrosis associated with Crohn’s disease, a condition in which scar tissue can narrow the intestine and contribute to complications.

The company also maintains earlier-stage discovery and development programs intended to apply its regenerative medicine expertise to additional gastrointestinal and oncology-related indications.